Therapeutic strategies in lymphoid malignancies : an immunotherapeutic approach

Contributors vii 1. The history of immunotherapy for lymphoid malignancies 1 Håkan Mellstedt 2. Immunologic markers of lymphoid malignancy 9 Andrew S. Jack 3. Diagnostic and prognostic markers of lymphoid malignancies; the latest genetic, cytogenic and haematological parameters 21 Terry J. Hamblin 4. CD20: B-cell antigen and therapeutic target 35 Peter McLaughlin, Julie P. Deans 5. Rituximab and chemotherapy for non-Hodgkin’s lymphomas: improved response and survival 45 Francisco J. Hernandez-Ilizaliturri, Myron Stefan Czuczman 6. Rituximab and chemotherapy in elderly patients with lymphomas 61 Bertrand Coiffier 7. Maintenance therapy with rituximab 69 Bruce D. Cheson, Blanche H. Mavromatis 8. Interferon-alpha in lymphoid malignancies 79 Jean-Luc Harousseau, Viviane Dubruille 9. Radioimmunotherapy safety: radiation protection, administration guidelines, isotope comparison, and quality of life issues 91 Brett Thomas Brinker, Leo I. Gordon 10. Radioimmunotherapy with Yttrium-90-labelled ibritumomab tiuxetan (Zevalin™) for B-cell non-Hodgkin’s lymphoma 101 Thomas E. Witzig 11. Radioimmunotherapy combinations with other therapies for non-Hodgkin’s lymphoma 115 Christos Emmanouilides 12. 131I-Tositumomab therapy for the treatment of low-grade non-Hodgkin’s lymphoma 123 Andrzej J. Jakubowiak, Mark S. Kaminski 13. CD52 as a target for immunotherapy 135 Martin J. S. Dyer 14. Relapsed and refractory CLL: a clinical challenge 143 Kanti R. Rai, N. Driscoll, D. M. Janson, D. V. Patel 15. Optimising the use of alemtuzumab in CLL: new therapeutic end-points, disease stratification and therapy earlier in the disease course 151 Peter Hillmen 16. Alemtuzumab in combination with other therapies in B-cell lymphoproliferative disorders 161 Karen W. L. Yee, Susan M. O’Brien 17. The role of alemtuzumab in allogeneic stem cell transplantation 177 Karl S. Peggs 18. Alemtuzumab in T-cell malignancies 189 Farhad Ravandi, Michael Keating 19. Epratuzumab: A new humanised monoclonal antibody to CD22 197 Morton Coleman, Richard R. Furman, Julian Decter, William A. Wegener, Ivan D. Horak, David M. Goldenberg, John P. Leonard 20. Education and management of patients undergoing immunotherapy and radioimmunotherapy 205 Nancy L. Tuinstra 21. Antibody therapy for chronic lymphocytic leukaemia 215 John C. Byrd, Kristie A. Blum, Thomas S. Lin